New cancer drug enters human testing for Tough-to-Treat tumors

NCT ID NCT05577182

Completed Disease control Sponsor: Incyte Corporation Source: ClinicalTrials.gov ↗

Summary

This early-stage study tested a new drug called INCA32459 in 46 people with advanced cancers that had stopped responding to standard treatments. The main goals were to find a safe dose and see how the body processes the drug. Researchers also looked for early signs that the drug might help control cancer growth.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Centro Integral Oncologico Clara Campal

Madrid, 28050, Spain
Centro Ricerche Cliniche Di Verona (Crc)

Verona, 37134, Italy
Chu Ucl Namur University Hospital Mont-Godinne

Yvoir, 05530, Belgium
Cliniques Universitaires Ucl Saint-Luc

Brussels, 01200, Belgium
Hospital Quironsalud Barcelona

Barcelona, 08023, Spain
Hospital Universitario 12 de Octubre

Madrid, 28041, Spain
Hospital Universitario Quironsalud Madrid

Pozuelo de Alarcón, 28223, Spain
Ico Institut Catala D Oncologia

L'Hospitalet de Llobregat, 08906, Spain
The Angeles Clinic and Research Institute

Los Angeles, California, 90025, United States
Universitair Ziekenhuis Antwerpen (Uza)

Edegem, 02650, Belgium
Universitair Ziekenhuis Brussel

Jette, 01090, Belgium
Universitair Ziekenhuis Gent

Ghent, 09000, Belgium
University of Texas Md Anderson Cancer Center

Houston, Texas, 77030, United States

Conditions

Explore the condition pages connected to this study.

ADVANCED MALIGNANCIES